Axogen Upsizes Public Offering to $124 Million—Early Debt Repayment and Growth in Focus
Market Chameleon (Thu, 22-Jan 8:19 AM)
Axogen Secures FDA Approval for AVANCE—A Major Regulatory Shift Sets the Stage for Nerve Repair Innovation
Market Chameleon (Thu, 4-Dec 10:03 AM)
FDA Greenlights Axogen’s Avance Biologic for Nerve Repair—What Does This Mean for Patients and Providers?
Market Chameleon (Thu, 4-Dec 7:50 AM)
